International Journal of Inflammation http://www.hindawi.com The latest articles from Hindawi Publishing Corporation © 2013 , Hindawi Publishing Corporation . All rights reserved. Curbing Inflammation in Burn Patients Mon, 20 May 2013 17:02:22 +0000 http://www.hindawi.com/journals/iji/2013/715645/ Patients who suffer from severe burns develop metabolic imbalances and systemic inflammatory response syndrome (SIRS) which can result in multiple organ failure and death. Research aimed at reducing the inflammatory process has yielded new insight into burn injury therapies. In this review, we discuss strategies used to curb inflammation in burn injuries and note that further studies with high quality evidence are necessary. Jayme A. Farina Jr., Marina Junqueira Rosique, and Rodrigo G. Rosique Copyright © 2013 Jayme A. Farina Jr. et al. All rights reserved. Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides Tue, 07 May 2013 09:30:06 +0000 http://www.hindawi.com/journals/iji/2013/985815/ The resolution of inflammation is now known to be an active process, armed with a multitude of mediators both lipid and protein in nature. Melanocortins are peptides endowed with considerable promise with their proresolution and anti-inflammatory effects in preclinical models of inflammatory disease, with tissue protective effects. These peptides and their targets are appealing because they can be seen as a natural way of inducing these effects as they harness endogenous pathways of control. Whereas most of the information generated about these mediators derives from several acute models of inflammation (such as zymosan induced peritonitis), there is some indication that these mediators may inhibit chronic inflammation by modulating cytokines, chemokines, and leukocyte apoptosis. In addition, proresolving mediators and their mimics have often been tested alongside therapeutic protocols, hence have been tested in settings more relevant to real life clinical scenarios. We provide here an overview on some of these mediators with a focus on melanocortin peptides and receptors, proposing that they may unveil new opportunities for innovative treatments of inflammatory arthritis. Tazeen J. Ahmed, Trinidad Montero-Melendez, Mauro Perretti, and Costantino Pitzalis Copyright © 2013 Tazeen J. Ahmed et al. All rights reserved. Evolution of the Macrophage CD163 Phenotype and Cytokine Profiles in a Human Model of Resolving Inflammation Thu, 02 May 2013 11:39:11 +0000 http://www.hindawi.com/journals/iji/2013/780502/ Cantharidin skin blisters were examined over two days to model the acute and resolving phases of inflammation in human skin. Four blisters were created by topical administration of cantharidin (0.1% v/v) to the forearm of healthy volunteers, with IRB approval. Duplicate skin blisters were aspirated at 16 and 40 hours to model the proinflammatory and resolving phases, respectively. There was a significant increase in leukocyte infiltrate at 40 h with appearance of a “resolving macrophage” phenotype CD14+CD163+ by flow cytometry. Neutrophils acquired apoptotic markers at 40 h and were observed to be phagocytosed by macrophagic “Reiter’s” cells. Multiplex cytokine analysis demonstrated that monocyte chemoattractant protein (MCP-1/CCL2), interleukin- (IL-) 6, IL-8/CXCL8, macrophage inflammatory protein (MIP1α/CCL3), MIP-1β/CCL4, tumor necrosis factor- (TNF-) α, and eotaxin (CCL11) were all significantly upregulated at 16 h compared with 40 h. In contrast, immunoregulatory transforming growth factor- (TGF-) β, macrophage-derived chemokine (MDC/CCL22), and interferon-inducible protein (IP-10/CXCL10) were significantly elevated at 40 h. Our results demonstrate that the phases of inflammation and resolution can be discriminated in a two-day model of dermal wound healing. This confirms and extends our understanding of wound repair in humans and provides a powerful research tool for use in clinical settings and to track the molecular benefits of therapeutic intervention. Betsy J. Evans, Dorian O. Haskard, Gregory Sempowksi, and R. Clive Landis Copyright © 2013 Betsy J. Evans et al. All rights reserved. Haptoglobin Genotype-Dependent Anti-Inflammatory Signaling in CD163+ Macrophages Tue, 23 Apr 2013 15:57:31 +0000 http://www.hindawi.com/journals/iji/2013/980327/ Intraplaque hemorrhage causes adaptive remodelling of macrophages towards a protective phenotype specialized towards handling iron and lipid overload, denoted Mhem. The Mhem phenotype expresses elevated levels of hemoglobin (Hb) scavenger receptor, CD163, capable of endocytosing pro-oxidant free Hb complexed to acute phase protein haptoglobin (Hp). It is notable that individuals homozygous for the Hp 2 allele (a poorer antioxidant) are at increased risk of cardiovascular disease compared to the Hp 1 allele. In this study, we examined whether scavenging of polymorphic Hp:Hb complexes differentially generated downstream anti-inflammatory signals in cultured human macrophages culminating in interleukin (IL)-10 secretion. We describe an anti-inflammatory signalling pathway involving phosphatidylinositol-3-kinase activation upstream of Akt phosphorylation (pSer473Akt) and IL-10 secretion. The pathway is mediated specifically through CD163 and is blocked by anti-CD163 antibody or phagocytosis inhibitor. However, levels of pSer473Akt and IL-10 were significantly diminished when scavenging polymorphic Hp2-2:Hb complexes compared to Hp1-1:Hb complexes . Impaired anti-inflammatory macrophage signaling through a CD163/pAkt/IL-10 axis may thus represent a possible Hp2-2 disease mechanism in atherosclerosis. R. Clive Landis, Pandelis Philippidis, Jan Domin, Joseph J. Boyle, and Dorian O. Haskard Copyright © 2013 R. Clive Landis et al. All rights reserved. Inflammation in Retinal Vein Occlusion Wed, 03 Apr 2013 13:22:50 +0000 http://www.hindawi.com/journals/iji/2013/438412/ Retinal vein occlusion is a common, vision-threatening vascular disorder. The role of inflammation in the pathogenesis and clinical consequences of retinal vein occlusion is a topic of growing interest. It has long been recognized that systemic inflammatory disorders, such as autoimmune disease, are a significant risk factor for this condition. A number of more recent laboratory and clinical studies have begun to elucidate the role inflammation may play in the molecular pathways responsible for the vision-impairing consequences of retinal vein occlusion, such as macular edema. This improved understanding of the role of inflammation in retinal vein occlusion has allowed the development of new treatments for the disorder, with additional therapeutic targets and strategies to be identified as our understanding of the topic increases. Avnish Deobhakta and Louis K. Chang Copyright © 2013 Avnish Deobhakta and Louis K. Chang. All rights reserved. Peripheral Fluorescein Angiographic Findings in Fellow Eyes of Patients with Branch Retinal Vein Occlusion Sun, 31 Mar 2013 11:20:58 +0000 http://www.hindawi.com/journals/iji/2013/464127/ Introduction. Branch retinal vein occlusion (BRVO) is a common retinal vascular condition that results in intraocular inflammatory changes. Ultra wide field fluorescein angiography (UWFFA) is a retinal imaging device that can capture peripheral retinal findings. The purpose of this study was to look for peripheral findings in the fellow eye of patients with BRVO using UWFFA. Methods. Retrospective imaging review of patients diagnosed with BRVO that had both eyes imaged with UWFFA. Images were graded for peripheral findings in other quadrants of the same eye as well as in all quadrants of the fellow eye. Results. Of 81 patients, 14 (17%) patients had late vascular leakage in a quadrant other than the BRVO distribution. Five (6%) findings were in the same eye, 8 (10%) findings were in the fellow eye, and 1 (1%) finding was in both the same eye and the fellow eye. Of these 14 patients, 11 (80%) patients had hypertension. Conclusion. Late peripheral retinal leakage in the fellow eye of patients with BRVO was detected in this cohort of patients with UWFFA. This novel finding may represent underlying systemic inflammation, hypertension, or bilateral BRVOs. Irena Tsui, Asima Bajwa, Valentina Franco-Cardenas, Carolyn K. Pan, Hanna Y. Kim, and Steven D. Schwartz Copyright © 2013 Irena Tsui et al. All rights reserved. Cardiovascular Inflammation 2012: Reactive Oxygen Species, SUMOylation, and Biomarkers in Cardiovascular Inflammation Sun, 10 Mar 2013 13:55:17 +0000 http://www.hindawi.com/journals/iji/2013/953463/ Jun-Ichi Abe, Ichiro Manabe, Masanori Aikawa, and Elena Aikawa Copyright © 2013 Jun-Ichi Abe et al. All rights reserved. Infiltration of Proinflammatory M1 Macrophages into the Outer Retina Precedes Damage in a Mouse Model of Age-Related Macular Degeneration Thu, 07 Mar 2013 10:56:44 +0000 http://www.hindawi.com/journals/iji/2013/503725/ Age-related macular degeneration (AMD) is a major cause of blindness in the developed world. Oxidative stress and inflammation are implicated in AMD, but precise mechanisms remain poorly defined. Carboxyethylpyrrole (CEP) is an AMD-associated lipid peroxidation product. We previously demonstrated that mice immunized with CEP-modified albumin developed AMD-like degenerative changes in the outer retina. Here, we examined the kinetics of lesion development in immunized mice and the presence of macrophages within the interphotoreceptor matrix (IPM), between the retinal pigment epithelium and photoreceptor outer segments. We observed a significant and time-dependent increase in the number of macrophages in immunized mice relative to young age-matched controls prior to overt pathology. These changes were more pronounced in BALB/c mice than in C57BL/6 mice. Importantly, IPM-infiltrating macrophages were polarized toward the M1 phenotype but only in immunized mice. Moreover, when Ccr2-deficient mice were immunized, macrophages were not present in the IPM and no retinal lesions were observed, suggesting a deleterious role for these cells in our model. This work provides mechanistic evidence linking immune responses against oxidative damage with the presence of proinflammatory macrophages at sites of future AMD and experimentally demonstrates that manipulating immunity may be a target for modulating the development of AMD. Fernando Cruz-Guilloty, Ali M. Saeed, Jose J. Echegaray, Stephanie Duffort, Asha Ballmick, Yaohong Tan, Michel Betancourt, Eduardo Viteri, Ghansham C. Ramkhellawan, Eric Ewald, William Feuer, DeQiang Huang, Rong Wen, Li Hong, Hua Wang, James M. Laird, Abdoulaye Sene, Rajendra S. Apte, Robert G. Salomon, Joe G. Hollyfield, and Victor L. Perez Copyright © 2013 Fernando Cruz-Guilloty et al. All rights reserved. Targeting Inflammation in Emerging Therapies for Genetic Retinal Disease Thu, 21 Feb 2013 09:31:11 +0000 http://www.hindawi.com/journals/iji/2013/581751/ Genetic retinal diseases such as age-related macular degeneration and monogenic diseases such as retinitis pigmentosa account for some of the commonest causes of blindness in the developed world. Diverse genetic abnormalities and environmental causes have been implicated in triggering multiple pathological mechanisms such as oxidative stress, lipofuscin deposits, neovascularisation, and programmed cell death. In recent years, inflammation has also been highlighted although whether inflammatory mediators play a central role in pathogenesis or a more minor secondary role has yet to be established. Despite this, numerous interventional studies, particularly targeting the complement system, are underway with the promise of novel therapeutic strategies for these important blinding conditions. Ishaq A. Viringipurampeer, Abu E. Bashar, Cheryl Y. Gregory-Evans, Orson L. Moritz, and Kevin Gregory-Evans Copyright © 2013 Ishaq A. Viringipurampeer et al. All rights reserved. Gab Docking Proteins in Cardiovascular Disease, Cancer, and Inflammation Tue, 22 Jan 2013 15:03:40 +0000 http://www.hindawi.com/journals/iji/2013/141068/ The docking proteins of the Grb2-associated binder (Gab) family have emerged as crucial signaling compartments in metazoans. In mammals, the Gab proteins, consisting of Gab1, Gab2, and Gab3, are involved in the amplification and integration of signal transduction evoked by a variety of extracellular stimuli, including growth factors, cytokines, antigens, and other molecules. Gab proteins lack the enzymatic activity themselves; however, when phosphorylated on tyrosine residues, they provide binding sites for multiple Src homology-2 (SH2) domain-containing proteins, such as SH2-containing protein tyrosine phosphatase 2 (SHP2), phosphatidylinositol 3-kinase regulatory subunit p85, phospholipase Cγ, Crk, and GC-GAP. Through these interactions, the Gab proteins transduce signals from activated receptors into pathways with distinct biological functions, thereby contributing to signal diversification. They are known to play crucial roles in numerous physiological processes through their associations with SHP2 and p85. In addition, abnormal Gab protein signaling has been linked to human diseases including cancer, cardiovascular disease, and inflammatory disorders. In this paper, we provide an overview of the structure, effector functions, and regulation of the Gab docking proteins, with a special focus on their associations with cardiovascular disease, cancer, and inflammation. Yoshikazu Nakaoka and Issei Komuro Copyright © 2013 Yoshikazu Nakaoka and Issei Komuro. All rights reserved. Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease Mon, 14 Jan 2013 09:22:39 +0000 http://www.hindawi.com/journals/iji/2013/281981/ Nonsteroidal anti-inflammatory drugs (NSAIDs) are used extensively in ophthalmology for pain and photophobia after photorefractive surgery and to reduce miosis, inflammation, and cystoid macular edema following cataract surgery. In recent years, the US Food and Drug Administration has approved new topical NSAIDs and previously approved NSAIDs have been reformulated. These changes may allow for greater drug penetration into the retina and thereby offer additional therapeutic advantages. For example, therapeutic effects on diabetic retinopathy and age-related macular degeneration may now be achievable. We provide an updated review on the scientific rationale and clinical use of NSAIDs for retinal disease. Scott D. Schoenberger and Stephen J. Kim Copyright © 2013 Scott D. Schoenberger and Stephen J. Kim. All rights reserved. Acute and Chronic Pancreatic Inflammation Thu, 03 Jan 2013 11:15:33 +0000 http://www.hindawi.com/journals/iji/2012/481658/ Derek A. O'Reilly, Zoltan Rakonczay Jr., and Marja-Leena Kylänpää Copyright © 2012 Derek A. O'Reilly et al. All rights reserved. The Clinical Course of Acute Pancreatitis and the Inflammatory Mediators That Drive It Wed, 12 Dec 2012 15:50:50 +0000 http://www.hindawi.com/journals/iji/2012/360685/ Acute pancreatitis (AP) is a common emergency condition. In the majority of cases, it presents in a mild and self-limited form. However, about 20% of patients develop severe disease with local pancreatic complications (including necrosis, abscess, or pseudocysts), systemic organ dysfunction, or both. A modern classification of AP severity has recently been proposed based on the factors that are causally associated with severity of AP. These factors are both local (peripancreatic necrosis) and systemic (organ failure). In AP, inflammation is initiated by intracellular activation of pancreatic proenzymes and/or nuclear factor-κB. Activated leukocytes infiltrate into and around the pancreas and play a central role in determining AP severity. Inflammatory reaction is first local, but may amplify leading to systemic overwhelming production of inflammatory mediators and early organ failure. Concomitantly, anti-inflammatory cytokines and specific cytokine inhibitors are produced. This anti-inflammatory reaction may overcompensate and inhibit the immune response, rendering the host at risk for systemic infection. Currently, there is no specific treatment for AP. However, there are several early supportive treatments and interventions which are beneficial. Also, increasing the understanding of the pathogenesis of systemic inflammation and the development of organ dysfunction may provide us with future treatment modalities. Leena Kylänpää, Zoltán Rakonczay Jr., and Derek A. O'Reilly Copyright © 2012 Leena Kylänpää et al. All rights reserved. Chemokine Expression in Human Astrocytes in Response to Shiga Toxin 2 Mon, 10 Dec 2012 15:53:05 +0000 http://www.hindawi.com/journals/iji/2012/135803/ Infection with Shiga toxin- (Stx-) producing Escherichia coli can lead to hemolytic uremic syndrome (HUS). Approximately, 30% of patients with HUS suffer from complications in the central nervous system (CNS), which is an important determinant of mortality in such patients. Autopsy shows mostly edema and hypoxic-ischemic changes in the CNS, often with microhemorrhages. It has been suggested that Stx-induced damage to human brain endothelial cells, which are essential constituents of the blood-brain barrier, plays a crucial role in the development of the CNS complications. However, it is unclear whether Stx affects brain neuroglial cells. In the present study, we investigated the direct involvement of Stx in the inflammatory responses of human astrocytes (HASTs) treated with Stx. Immunohistochemistry and real-time PCR revealed that the expression of globotriaosylceramide (Gb3), the receptor for Stx2, and Gb3 synthase (GalT6) in HASTs was increased by interleukin-1β (IL-1β). Expression of both interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) mRNA in HASTs was significantly upregulated by Stx2. These results suggest that Stx2 induces inflammatory responses, particularly through expression of chemokines, in HASTs expressing Gb3 and may, thus, affect brain glial cells, playing a key role in the pathogenesis of CNS manifestations associated with HUS. Naomi Kioka, Koichi Minami, Akira Tamura, and Norishige Yoshikawa Copyright © 2012 Naomi Kioka et al. All rights reserved. The Immune Response: Targets for the Treatment of Severe Sepsis Mon, 03 Dec 2012 16:02:44 +0000 http://www.hindawi.com/journals/iji/2012/697592/ The clinical process of severe sepsis is characterized by extreme inflammation interlinked with potent stimulation of the coagulation cascade often followed by a state of relative immune paralysis. In this paper, we will review many of the potential therapies directed at various steps along the inflammatory cascade from modulation of inflammatory mediators eliciting the immune response, alteration of the host's immune response in both a stimulatory and depressive manner, and taming the overexuberant coagulation response triggered by the fierce coagulation-inflammation cycle. Finally, we will discuss further opportunities for research to improve our ability to design effective therapies. Aline M. Bernard and Gordon R. Bernard Copyright © 2012 Aline M. Bernard and Gordon R. Bernard. All rights reserved. Rapamycin Augments the NMDA-Mediated TNF Suppression of MRSA-Stimulated RAW264.7 Murine Macrophages Wed, 10 Oct 2012 12:47:13 +0000 http://www.hindawi.com/journals/iji/2012/542727/ Background. Methicillin-resistant Staphylococcus aureus (MRSA) can stimulate massive cytokine release. Ketamine suppresses tumor necrosis factor (TNF) secretion by MRSA-stimulated RAW264.7 macrophages, and the mechanism likely involves N-methyl-D-aspartic acid (NMDA) receptor antagonism. The downstream effects of NMDA-mediated TNF suppression, specifically the PI3K/Akt and mTOR modulation, have not been described. Methods. RAW264.7 cells were stimulated for 18 hrs with 105 to 107 CFU/mL inocula of either of two prototypical community-acquired- (CA-) MRSA isolates, USA300 strain LAC and USA400 strain MW2. Then we added the NMDA inhibitors ketamine or 2R-amino-5-phosphonopentanoate (AP5), NMDA substrate, LY294002, and rapamycin in various combinations. Results. NMDA inhibition suppressed TNF secretion by almost a third compared to the no-ketamine control. When NMDA substrate was added, the TNF secretion increased by 10%. Addition of LY294002 suppressed TNF production by macrophages by 20%. Rapamycin exhibited a concentration-dependent TNF induction-suppression response: induction at doses of 0.1 and 1 ng/mL and suppression at 10 and 100 ng/mL. Induction of TNF was abolished when LY294002 was added and the suppression became uniform. Ketamine-induced suppression of TNF secretion was intensified 10–15% when rapamycin was added, but not when LY294002 was added. Conclusion. These findings suggest that NMDA-induced TNF suppression can be augmented by concurrent mTOR inhibition. Thomas Spentzas, Rebekah K. H. Shappley, Fabio Savorgnan, Elizabeth Meals, and B. Keith English Copyright © 2012 Thomas Spentzas et al. All rights reserved. Ocular Inflammation and Infection Thu, 04 Oct 2012 11:35:38 +0000 http://www.hindawi.com/journals/iji/2012/403520/ Michelle Callegan, Meredith Gregory-Ksander, Mark Willcox, and Susan Lightman Copyright © 2012 Michelle Callegan et al. All rights reserved. Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation Thu, 06 Sep 2012 08:35:33 +0000 http://www.hindawi.com/journals/iji/2012/678190/ Although the exact mechanism through which NADPH oxidases (Nox’s) generate reactive oxygen species (ROS) is still not completely understood, it is widely considered that ROS accumulation is the cause of oxidative stress in endothelial cells. Increasing pieces of evidence strongly indicate the role for ROS in endothelial inflammation and dysfunction and subsequent development of atherosclerotic plaques, which are causes of various pathological cardiac events. An overview for a causative relationship between ROS and endothelial inflammation will be provided in this review. Particularly, a crucial role for specific protein SUMOylation in endothelial inflammation will be presented. Given that SUMOylation of specific proteins leads to increased endothelial inflammation, targeting specific SUMOylated proteins may be an elegant, effective strategy to control inflammation. In addition, the involvement of ROS production in increasing the risk of recurrent coronary events in a sub-group of non-diabetic, post-infarction patients with elevated levels of HDL-cholesterol will be presented with the emphasis that elevated HDL-cholesterol under certain inflammatory conditions can lead to increased incidence of cardiovascular events. Nhat-Tu Le, James P. Corsetti, Janet L. Dehoff-Sparks, Charles E. Sparks, Keigi Fujiwara, and Jun-ichi Abe Copyright © 2012 Nhat-Tu Le et al. All rights reserved. Serum Levels of Gelatinase Associated Lipocalin as Indicator of the Inflammatory Status in Coronary Artery Disease Tue, 04 Sep 2012 11:56:12 +0000 http://www.hindawi.com/journals/iji/2012/189797/ Background. Atherosclerosis is a chronic inflammatory disease and the acute clinical manifestations represent acute on chronic inflammation. Neutrophil gelatinase-associated lipocalin (NGAL) is found in the granules of human neutrophils, with many diverse functions. The aim of this study was to evaluate the hypothesis that levels NGAL in blood may reflect the inflammatory process in various stages of coronary artery disease. Methods. We studied 140 patients, with SA 40, UA 35, NSTEMI 40, and STEMI 25, and 20 healthy controls. Serum NGAL was measured upon admission and before coronary angiography. Results. Significant differences were observed in median serum-NGAL(ng/mL) between patients with SA (79.23 (IQR, 37.50–100.32)), when compared with UA (108.00 (68.34–177.59)), NSTEMI (166.49 (109.24–247.20)), and STEMI (178.63 (111.18–305.92)) patients and controls (50.31 (44.30–69.78)) with significant incremental value from SA to STEMI. We observed a positive and significant correlation between serum-NGAL and hs-CRP (spearman coefficient rho = 0.685, 𝑃<0.0001) as well as with neutrophil counts (r = 0.511, 𝑃<0.0001). Conclusions. In patients with coronary artery disease serum levels of NGAL increase and reflect the degree of inflammatory process. In patients with acute coronary syndromes, serum levels of NGAL have high negative predictive value and reflecting the inflammatory status could show the severity of coronary clinical syndrome. Nikolaos Kafkas, Christos Demponeras, Filitsa Zoubouloglou, Loukia Spanou, Dimitrios Babalis, and Konstantinos Makris Copyright © 2012 Nikolaos Kafkas et al. All rights reserved. Adult Onset Still's Disease and Autoinflammation Wed, 29 Aug 2012 08:06:24 +0000 http://www.hindawi.com/journals/iji/2012/964751/ Petros Efthimiou, L. Nandini Moorthy, Clio P. Mavragani, Dimitris Skokos, and Bruno Fautrel Copyright © 2012 Petros Efthimiou et al. All rights reserved. Association between Serum Uric Acid Levels and Sleep Variables: Results from the National Health and Nutrition Survey 2005–2008 Tue, 28 Aug 2012 14:09:21 +0000 http://www.hindawi.com/journals/iji/2012/363054/ Sleep disordered breathing as well as high serum uric acid levels are independent risk factors for cardiovascular disease. However, studies evaluating the relationship between sleep-disordered breathing and hyperuricemia are limited. We examined the 2005–2008 National Health and Nutrition Examination survey's sleep variables and high serum uric acid among 6491 participants aged β‰₯20 years. The sleep variables included sleep duration, snoring, snorting, and daytime sleepiness. The main outcome was high serum uric acid level, defined as levels of serum uric acid >6.8 mg/dL in males and >6.0 mg/dL in females. We found that snoring more than 5 nights per week, daytime sleepiness, and an additive composite score of sleep variables were associated with high serum uric acid in the age- , sex-adjusted model and in a multivariable model adjusting for demographic and lifestyle/behavioral risk factors. The association was attenuated with the addition of variables related to clinical outcomes such as depression, diabetes, hypertension, and high-cholesterol levels. Our results indicate a positive relationship between sleep variables, including the presence of snoring, snorting, and daytime sleepiness, and high serum uric acid levels. R. Constance Wiener and Anoop Shankar Copyright © 2012 R. Constance Wiener and Anoop Shankar. All rights reserved. Erratum to “Ferritin in Adult-Onset Still’s Disease: Just a Useful Innocent Bystander?” Sun, 26 Aug 2012 14:18:57 +0000 http://www.hindawi.com/journals/iji/2012/254858/ Bella Mehta and Petros Efthimiou Copyright © 2012 Bella Mehta and Petros Efthimiou. All rights reserved. Anti-Inflammatory Effects of Interleukin-19 in Vascular Disease Sun, 15 Jul 2012 11:34:34 +0000 http://www.hindawi.com/journals/iji/2012/253583/ Despite aggressive dietary modification, lipid-lowering medications, and other interventional medical therapy, vascular disease continues to be a leading cause of mortality in the western world. It is a significant medical and socioeconomic problem contributing to mortality of multiple diseases including myocardial infarction, stroke, renal failure, and peripheral vascular disease. Morbidity and mortality of vascular disease are expected to worsen with the increasing number of patients with comorbid conditions such as obesity, metabolic syndrome, and diabetes mellitus type 2. Vascular diseases such as atherosclerosis, restenosis, and allograft vasculopathy are recognized to be driven by inflammation, and as such, cytokines which mediate inflammation not only represent important targets of rational therapy, but also can be considered as possible therapeutic modalities themselves. In this paper, we will examine the role of inflammatory cytokines and lymphocyte Th1/Th2 polarity in vascular inflammation, with a focus on atherosclerotic vascular disease. We will then introduce a recently described Th2 interleukin, interleukin-19 (IL-19), as a previously unrecognized mediator of vascular inflammatory disorders. We will review our current understanding of this interleukin in health and disease and present the possibility that IL-19 could represent a potential therapeutic to combat vascular inflammatory disease. Ross N. England and Michael V. Autieri Copyright © 2012 Ross N. England and Michael V. Autieri. All rights reserved. Vascularisation Pattern of Chronic Pancreatitis Compared with Pancreatic Carcinoma: Results from Contrast-Enhanced Endoscopic Ultrasound Tue, 10 Jul 2012 14:48:20 +0000 http://www.hindawi.com/journals/iji/2012/420787/ Discriminating between focal chronic pancreatitis and pancreatic cancer is always a challenge in clinical medicine. Contrast-enhanced endoscopic ultrasound using Doppler techniques can uniquely reveal different vascularisation patterns in pancreatic tissue alterated by chronic inflammatory processes and even allows a discrimination from pancreatic cancer. This paper will describe the basics of contrast-enhanced high mechanical index endoscopic ultrasound (CEHMI EUS) and contrast enhanced low mechanical index endoscopic ultrasound (CELMI EUS) and explain the pathophysiological differences of the vascularisation of chronic pancreatitis and pancreatic carcinoma. Furthermore it will discuss how to use these techniques in daily clinical practice. Michael Hocke and Christoph F. Dietrich Copyright © 2012 Michael Hocke and Christoph F. Dietrich. All rights reserved. The Role of S100A12 as a Systemic Marker of Inflammation Tue, 03 Jul 2012 08:21:12 +0000 http://www.hindawi.com/journals/iji/2012/907078/ S100A12 is a member of the S100 family of calcium-binding proteins with important extracellular activities. In recent years, investigators across a number of fields have delineated the patterns of S100A12 expression in a variety of conditions. These data suggest that S100A12 can be used as a valuable serum inflammatory marker. B. Meijer, R. B. Gearry, and A. S. Day Copyright © 2012 B. Meijer et al. All rights reserved. Adult-Onset Still’s Disease: From Pathophysiology to Targeted Therapies Tue, 26 Jun 2012 15:51:27 +0000 http://www.hindawi.com/journals/iji/2012/879020/ Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder affecting primarily young individuals. The diagnosis is primarily clinical and necessitates the exclusion of a wide range of mimicking disorders. Given the lack of solid data in regard to the underlying pathogenetic mechanisms, treatment of AOSD has been for years largely empirical. Recent advances have revealed a pivotal role of several proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-18 (IL-18) in disease pathogenesis, giving rise to the development of new targeted therapies aiming at optimal disease control. Clio P. Mavragani, Evangelos G. Spyridakis, and Michael Koutsilieris Copyright © 2012 Clio P. Mavragani et al. All rights reserved. IL-18 Serum Level in Adult Onset Still’s Disease: A Marker of Disease Activity Mon, 18 Jun 2012 14:28:07 +0000 http://www.hindawi.com/journals/iji/2012/156890/ Introduction. Immunological factors seem to play a pivotal role in Adult Onset Still's Disease (AOSD). Among all, IL-18 cytokine is overexpressed and drives the inflammatory process. Objective. We aimed to investigate the levels of IL-18 in sera of Italian patients with AOSD and to assess its possible role as a marker of disease activity. Methods. IL-18 serum levels were determined by ELISA in 26 Italian patients with AOSD. Disease activity was assessed using Pouchot’s criteria. As controls, 21 patients with Rheumatoid Arthritis (RA), 21 patients with Sjogren's Syndrome (SS), 20 patients with Systemic Lupus Erythematosus (SLE), and 21 healthy subjects (normal human sera, NHS) were evaluated. Results. IL-18 serum levels were significantly higher in patients with active AOSD than in non-active (𝑃=0.001) and control groups (RA 𝑃=0.0070, SS 𝑃=0.0029, SLE 𝑃=0.0032, NHS 𝑃=0.0004). A significant correlation between IL-18 serum levels and disease activity (𝑃<0.0001), and laboratory parameters as ferritin (𝑃=0.0127) and C-reactive protein (𝑃=0.0032) was demonstrated. Conclusions. Higher levels of IL-18 are detected in active AODS patients and correlate with disease activity and inflammatory laboratory features. ROC-AUC analysis of the serum concentration of IL-18 suggests that it can be considered a diagnostic marker of AOSD. This paper supports the targeting of this cytokine as a possible therapeutic option in AOSD. Serena Colafrancesco, Roberta Priori, Cristiano Alessandri, Carlo Perricone, Monica Pendolino, Giovanna Picarelli, and Guido Valesini Copyright © 2012 Serena Colafrancesco et al. All rights reserved. Intragastric and Intranasal Administration of Lactobacillus paracasei NCC2461 Modulates Allergic Airway Inflammation in Mice Tue, 12 Jun 2012 08:47:01 +0000 http://www.hindawi.com/journals/iji/2012/686739/ Introduction. Preclinical and clinical evidences for a role of oral probiotics in the management of allergic diseases are emerging. Aim. We aimed at testing the immunomodulatory effects of intranasal versus intragastric administration of Lactobacillus paracasei NCC2461 in a mouse model of allergic airway inflammation and the specificity of different probiotics by comparing L. paracasei NCC2461 to Lactobacillus plantarum NCC1107. Methods. L. paracasei NCC2461 or L. plantarum NCC1107 strains were administered either intragastrically (NCC2461) or intranasally (NCC2461 or NCC1107) to OVA-sensitized mice challenged with OVA aerosols. Inflammatory cell recruitment into BALF, eotaxin and IL-5 production in the lungs were measured. Results. Intranasal L. paracasei NCC2461 efficiently protected sensitized mice upon exposure to OVA aerosols in a dose-dependent manner as compared to control mice. Inflammatory cell number, eotaxin and IL-5 were significantly reduced in BALF. Intranasal supplementation of L. paracasei NCC2461 was more potent than intragastric application in limiting the allergic response and possibly linked to an increase in T regulatory cells in the lungs. Finally, intranasal L. plantarum NCC1107 reduced total and eosinophilic lung inflammation, but increased neutrophilia and macrophages infiltration. Conclusion. A concerted selection of intervention schedule, doses, and administration routes (intranasal versus intragastric) may markedly contribute to modulate airway inflammation in a probiotic strain-specific manner. Céline Pellaton, Sophie Nutten, Anne-Christine Thierry, Caroline Boudousquié, Nathalie Barbier, Carine Blanchard, Blaise Corthésy, Annick Mercenier, and François Spertini Copyright © 2012 Céline Pellaton et al. All rights reserved. Proinflammatory Effects of C-Peptide in Different Tissues Mon, 11 Jun 2012 13:01:07 +0000 http://www.hindawi.com/journals/iji/2012/932725/ Atherosclerosis is well known as an inflammatory disease that can lead to clinical complications such as heart attack or stroke. C-peptide as a cleavage product of proinsulin is in the last few decades known as an active peptide with a number of different effects on microvascular and macrovascular complications in type 2 diabetic patients. Patients with insulin resistance and early type 2 diabetes show elevated levels of C-peptide in blood. Several last findings demonstrated deposition of C-peptide in the vessel wall in ApoE-deficient mice and induction of local inflammation. Besides that, C-peptide has proliferative effects on human mesangial cells. This review discusses recently published proinflammatory effects of C-peptide in different tissues. Dusica Vasic and Daniel Walcher Copyright © 2012 Dusica Vasic and Daniel Walcher. All rights reserved. Biomarkers of Chronic Inflammatory State in Uremia and Cardiovascular Disease Mon, 04 Jun 2012 14:36:11 +0000 http://www.hindawi.com/journals/iji/2012/360147/ Cardiovascular disease is the leading cause of death in the general population; traditional risk factors seem inadequate to explain completely the remarkable prevalence of cardiovascular mortality and morbidity observed in the uremic population. A role for chronic inflammation has been well established in the development of atherosclerotic disease, and, on the basis of these observations, atherosclerosis might be considered an inflammatory disease. Inflammation has been implicated in the etiology of coronary artery disease in the general population, and traditional inflammatory biomarkers such as C-reactive protein (CRP) and interleukin-6 (IL-6) have been shown to predict cardiovascular events in both symptomatic and asymptomatic individuals as well as those in the uremic population. Later on, new nontraditional markers were related to the risk of cardiovascular morbidity and mortality in general and in uremic population. As a consequence of the expanding research base and availability of assays, the number of inflammatory marker tests ordered by clinicians for cardiovascular disease (CVD) risk prediction has grown rapidly and several commercial assays have become available. So, up to now we can consider that several new nontraditional markers as CD40-CD40 ligand system and pentraxin-3 seem to be significant features of cardiovascular disease in general and in ESRD population. Vincenzo Panichi, Alessia Scatena, Massimiliano Migliori, Valentina Marchetti, Sabrina Paoletti, and Sara Beati Copyright © 2012 Vincenzo Panichi et al. All rights reserved.